<- Go Home
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
Market Cap
$2.1B
Volume
1.3M
Cash and Equivalents
$79.8M
EBITDA
$2.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$235.9M
Profit Margin
94.91%
52 Week High
$23.57
52 Week Low
$6.38
Dividend
N/A
Price / Book Value
21.42
Price / Earnings
-7.5K
Price / Tangible Book Value
25.85
Enterprise Value
$2.1B
Enterprise Value / EBITDA
568.72
Operating Income
-$977.0K
Return on Equity
0.32%
Return on Assets
-0.34
Cash and Short Term Investments
$91.6M
Debt
$37.4M
Equity
$98.2M
Revenue
$248.5M
Unlevered FCF
$8.8M
Sector
Pharmaceuticals
Category
N/A